GlassScriptPhysician profile
Lydia Rabinowich
NPI 1003803305
$4,497.21
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,428 · 2020: $1,198 · 2021: $1,008 · 2022: $840 · 2024: $23.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $23.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $683.19 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $471.13 | 2020-2022 | |
| Abbott Laboratories | $374.73 | 2019-2024 | Infinity |
| Emd Serono, INC. | $289.61 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $284.46 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $267.17 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $239.95 | 2019-2021 | |
| Biogen, INC. | $238.99 | 2019-2021 | |
| Mdd US Operations, LLC | $190.97 | 2019-2022 | |
| Allergan, INC. | $151.94 | 2019-2020 | |
| Genzyme Corporation | $140.67 | 2019-2021 | |
| Amgen INC. | $139.44 | 2019-2022 | |
| Pfizer INC. | $107.56 | 2019-2022 | |
| Kyowa Kirin, INC. | $105.58 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $98.42 | 2019-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $96.09 | 2021 | |
| Vertical Pharmaceuticals, LLC | $63.27 | 2019 | |
| Horizon Therapeutics Plc | $55.35 | 2021-2022 | |
| Csl Behring | $46.75 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $44.51 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $41.78 | 2022 | |
| Medtronic USA, INC. | $39.86 | 2019 | |
| Ucb, INC. | $39.39 | 2019 | |
| Ge Healthcare | $35.02 | 2022 | |
| Bausch Health US, LLC | $33.19 | 2019 | |
| Neurocrine Biosciences, INC. | $24.23 | 2021 | |
| Acorda Therapeutics, INC | $23.33 | 2019 | |
| Sunovion Pharmaceuticals INC. | $20.86 | 2020 | |
| Lilly USA, LLC | $19.91 | 2022 | |
| Eisai INC. | $18.55 | 2019 | |
| Lundbeck LLC | $17.86 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $17.43 | 2019 | |
| Grifols USA, LLC | $17.39 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.13 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.79 | 2021 | |
| Akcea Therapeutics, INC. | $13.92 | 2019 | |
| Avion Pharmaceuticals | $13.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Rabinowich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.